A cardiac catheterization that shows open coronary arteries does not mean your chest pain is imaginary or that your heart is fine. An estimated three to four million people in the United States alone have signs of cardiac ischemia, meaning the heart muscle is not getting enough blood, despite having no significant blockage on angiography.1PubMed. Ischemia with No Obstructive Arteries (INOCA): A Review of the Prevalence, Diagnosis and Management The medical term for this is INOCA (ischemia with no obstructive coronary artery disease), and it is a real, diagnosable, treatable set of conditions. What happens next depends on figuring out which mechanism is behind your symptoms.
Why Clean Arteries Do Not Always Mean a Healthy Heart
Standard catheterization is designed to find plaque-based blockages in the large coronary arteries. It does that job well. But the large arteries are only part of the story. Most of the blood supply to your heart muscle flows through a vast network of tiny vessels, the coronary microcirculation, that are too small to show up on an angiogram. Problems in those vessels, or spasms in the larger ones that come and go, or structural quirks in the way an artery sits within the heart muscle can all produce genuine ischemia. None of them will appear on a routine cath.
Too often, patients are told their heart looks fine and sent home without further investigation. That approach misses real conditions and leaves people stuck with ongoing chest pain and no explanation.2PubMed Central. Chest pain with angiographic clear coronary arteries: A provider’s approach to cardiac syndrome X The following sections cover the cardiac causes most commonly responsible, the non-cardiac possibilities worth ruling out, and the treatments available once a specific diagnosis is made.
Coronary Microvascular Dysfunction
Coronary microvascular dysfunction, or CMD, is probably the most common cardiac explanation for chest pain with open arteries. It refers to a range of problems in the smallest coronary vessels, including structural changes that narrow them and functional problems that prevent them from dilating properly when your heart demands more blood.3PubMed Central. Coronary microvascular dysfunction: pathophysiology, diagnosis, and therapeutic strategies across cardiovascular diseases The result is the same as a blockage in a large artery: the heart muscle does not get enough oxygen, and you feel chest pain, shortness of breath, or fatigue with exertion.
The underlying causes of CMD are varied and still being worked out. Researchers have identified endothelial dysfunction (where the lining of the tiny vessels does not relax properly), chronic inflammation, oxidative stress, and even mitochondrial abnormalities in the heart muscle itself as contributing factors.4Metabolism and Target Organ Damage. The emerging pathological mechanism of coronary microvascular dysfunction: a narrative review CMD is not a single disease so much as an umbrella for several overlapping dysfunctions that all converge on the same problem: your small vessels are not delivering blood the way they should.
Autoimmune and inflammatory conditions can amplify this. In patients with systemic lupus erythematosus who have chest pain and suspected INOCA, roughly half show evidence of coronary microvascular dysfunction on testing.5PubMed Central. Coronary Microvascular Dysfunction in Patients With Systemic Lupus Erythematosus and Chest Pain If you have an autoimmune condition and unexplained angina, CMD should be high on the list of suspects.
Coronary Artery Spasm
Sometimes the large coronary arteries look perfectly normal on catheterization because the problem is not structural but functional: the artery periodically clenches shut in a spasm, temporarily choking off blood flow. This is called vasospastic angina. Unlike the steady, predictable pain of a fixed blockage, vasospastic episodes tend to strike at rest, often in the early morning hours, and can be severe. Beyond chest pain, coronary spasm can cause heart attacks, impair heart function, trigger dangerous arrhythmias, and in extreme cases cause sudden cardiac death.6PubMed Central. Coronary artery spasm: Current knowledge and residual uncertainties
The tricky part is that by the time you are on the cath table, the spasm has usually resolved. Your arteries look wide open because they are wide open at that moment. Catching vasospastic angina requires provocation testing, typically done with a drug called acetylcholine injected directly into the coronary artery during the catheterization procedure. In one large series of over 700 patients with chest pain and no obstructive disease, acetylcholine provocation revealed epicardial spasm in about 44% of those tested.7PubMed Central. Intracoronary acetylcholine testing among 746 consecutive Japanese patients with angina-like chest pain and unobstructed coronary artery disease That is a striking number. It means a very large share of patients with unexplained chest pain have coronary spasm lurking behind the clean angiogram, but you will never find it if you do not look for it.
Microvascular spasm is another possibility. In the same study, about 5% of patients had spasm localized to the tiny vessels rather than the large arteries.7PubMed Central. Intracoronary acetylcholine testing among 746 consecutive Japanese patients with angina-like chest pain and unobstructed coronary artery disease This is harder to diagnose because the small vessels cannot be seen on angiography even when they are spasming; the diagnosis depends on reproducing the patient’s symptoms and characteristic ECG changes during acetylcholine injection without visible large-vessel narrowing.
Myocardial Bridging
A myocardial bridge is an anatomical variant where a segment of a coronary artery dips into the heart muscle instead of lying on the surface. During each heartbeat, the surrounding muscle squeezes the buried segment of the artery. In most people this causes no trouble, but in some it produces exertional chest pain, especially when the heart rate is high and the artery spends less time relaxed between beats. Myocardial bridging is present in up to a third of adults, though symptomatic cases are far less common.8PubMed. Prevalence of myocardial bridging associated with coronary endothelial dysfunction in patients with chest pain and non-obstructive coronary artery disease
The link between bridging and symptoms is not straightforward. Bridging tends to coexist with endothelial dysfunction in the artery segment downstream of the bridge. In one study of symptomatic patients with non-obstructive disease, those with a myocardial bridge had a significantly higher frequency of endothelial dysfunction in the affected vessel compared to patients without bridging. Bridging also predicted microvascular endothelial dysfunction.8PubMed. Prevalence of myocardial bridging associated with coronary endothelial dysfunction in patients with chest pain and non-obstructive coronary artery disease In other words, the bridge itself may not be the whole problem; it may be damaging the vessel lining over time, creating a downstream dysfunction that amplifies symptoms.
Diagnosing a symptomatic bridge usually requires more than standard angiography. Specialized pressure and flow measurements during the cath can determine whether the bridge is actually restricting blood flow enough to explain symptoms. In one reported case, standard resting measurements were normal, but measurements taken during drug-induced stress revealed significant flow restriction across the bridged segment.9PubMed Central. Going under the bridge: unmasking ischaemia and endothelial dysfunction of myocardial bridging: a case report
Non-Cardiac Causes Worth Ruling Out
Not all chest pain comes from the heart, and if your catheterization was clean and further cardiac workup does not reveal CMD, spasm, or a bridge, the pain may originate somewhere else entirely. The chest is a crowded neighborhood, and the heart shares nerve pathways with the esophagus, the chest wall, and the lungs. Pain from any of those structures can feel identical to cardiac angina.
Gastrointestinal causes are the most common non-cardiac explanation. Gastroesophageal reflux disease and esophageal motility disorders such as esophageal spasm can produce retrosternal pain that is clinically indistinguishable from heart-related chest pain. Because the esophagus and heart share the same nerve fibers, acid reflux can trigger pain in the exact same spot. Up to half of patients with non-cardiac chest pain have underlying GERD.10PubMed Central. Diagnosis and management of esophageal chest pain A trial of acid-suppressing medication is often one of the first steps once cardiac causes are excluded.
Musculoskeletal problems are another frequent culprit. Costochondritis, inflammation of the cartilage connecting the ribs to the breastbone, can produce sharp or aching pain that worsens with movement or pressure. A rarer cousin called Tietze’s syndrome produces visible swelling in the same area. These are benign and self-limiting but notoriously difficult to diagnose because they mimic cardiac pain so convincingly.11Quality in Sport. Understanding Tietze’s Syndrome: A Rare and Often Overlooked Cause of Anterior Chest Wall Pain
Psychological factors deserve mention too, though not as a dismissal. At least half of patients with non-cardiac chest pain have a coexisting psychiatric condition such as anxiety or depression.12PubMed Central. Diagnosis and Management of Noncardiac Chest Pain The relationship between the mind and chest pain is not simple or one-directional. Panic disorder can produce genuine chest pain through hyperventilation and autonomic activation. Conversely, chronic unexplained chest pain can breed anxiety and hypervigilance, which then amplify the pain signal. Mechanisms like heightened sensitivity to normal cardiopulmonary sensations, poor coping strategies, and fear of heart disease all feed the cycle.13PubMed Central. The Role of Psychological Factors in Noncardiac Chest Pain of Esophageal Origin Treating the psychological component is not about telling you the pain is in your head. It is about recognizing that pain and distress reinforce each other and that addressing both produces better outcomes than addressing either alone.
What Testing Comes After a Normal Catheterization
If your cardiologist suspects a cardiac cause beyond what the standard cath revealed, additional testing can pin down the specific problem. The tests fall into two broad categories: invasive procedures done during or shortly after catheterization, and non-invasive imaging.
Coronary reactivity testing is the reference standard for evaluating microvascular and epicardial function. It involves injecting vasoactive agents like acetylcholine directly into the coronary arteries during catheterization and measuring how the vessels respond. Acetylcholine normally causes arteries to dilate. If it triggers spasm instead, that is diagnostic. If the large arteries look fine but you develop chest pain and ECG changes during the injection, the spasm is microvascular. Simultaneously measuring coronary flow reserve and microvascular resistance using specialized wires can identify CMD even in the absence of spasm.14PubMed Central. Coronary Microvascular Disease in Contemporary Clinical Practice This comprehensive testing has both diagnostic and prognostic value, particularly for women with INOCA.15PubMed Central. The role of coronary reactivity testing in women with no obstructive coronary artery disease
On the non-invasive side, stress perfusion imaging can detect microvascular dysfunction without another catheterization. Positron emission tomography (PET) is considered the gold standard non-invasive method for evaluating microvascular blood flow. Cardiac magnetic resonance imaging (MRI) with stress perfusion protocols is an emerging alternative that avoids radiation exposure and can quantify how well blood reaches the heart muscle during pharmacological stress.16PubMed Central. Coronary Microvascular Dysfunction: PET, CMR and CT Assessment Recent work using quantitative perfusion by cardiac MRI has shown promising results for non-invasively detecting vasomotor dysfunction in patients with angina and non-obstructive arteries.17PubMed. Quantitative perfusion by cardiac magnetic resonance imaging reveals compromised myocardial perfusion in patients with angina with non-obstructive coronary artery disease These non-invasive approaches are especially useful for patients who are not candidates for another catheterization or for monitoring treatment response over time.
Treatment Once You Have a Diagnosis
Treatment depends entirely on which condition is identified. The three most common cardiac diagnoses after a clean cath, CMD, vasospastic angina, and myocardial bridging, each call for a different approach, though there is some overlap.
For coronary microvascular dysfunction, first-line treatment typically starts with standard anti-ischemic medications: beta-blockers, calcium channel blockers, and nitrates. The reality is that symptom control with these drugs alone is often insufficient.18PubMed. Management of microvascular angina pectoris When first-line drugs fall short, ranolazine is one of the better-studied additions. It works through a different mechanism than traditional angina drugs, and evidence shows it significantly improves symptoms and quality of life in patients with microvascular angina who have not responded well to initial treatment.19PubMed. Ranolazine for Symptomatic Management of Microvascular Angina ACE inhibitors combined with statins have also shown benefit by improving endothelial function through their anti-inflammatory and antioxidant effects, with six months of combined therapy improving both blood vessel function and daily-life symptoms in CMD patients.20PubMed Central. Efficacy of Angiotensin-Converting Enzyme Inhibitors in Coronary Microvascular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
An ongoing clinical trial called STAR-INOCA is testing a stepwise treatment approach for CMD: starting with statins, beta-blockers, and ACE inhibitors, then adding a calcium channel blocker if angina persists, and finally adding ranolazine as a third step if symptoms still are not controlled. This trial will provide the first prospective evaluation of that sequential strategy using both objective measurements of coronary flow and patient-reported outcomes.21PubMed. Effect of State-of-the-Art Treatment on Symptoms, Absolute Coronary Artery Flow, and Resistance Among Patients With Ischemia and Non-Obstructive Coronary Arteries (STAR-INOCA Study): Study Design and Rationale
For vasospastic angina, calcium channel blockers are the cornerstone of therapy, with nitrates used as an add-on.22International Seven Journal of Multidisciplinary. THERAPEUTIC MANAGEMENT OF VASOSPASTIC ANGINA: STABILIZATION STRATEGIES AND ANTITHROMBOTIC THERAPY Among the calcium channel blockers, diltiazem and nifedipine are both effective at reducing the frequency of angina episodes. Diltiazem tends to show a slight edge at maintaining suppression over longer periods, while nifedipine works faster in the first few weeks but can cause blood pressure drops and a faster heart rate. Amlodipine is another option that decreased weekly chest pain frequency and rendered about a third of patients pain-free after six weeks of treatment.23BMJ. Comparison of various calcium antagonist on vasospastic angina: a systematic review One critical point for vasospastic angina: beta-blockers, which are first-line for many heart conditions, can actually make coronary spasm worse by leaving the artery’s constriction pathways unopposed. If your diagnosis is vasospasm, your doctor should be choosing calcium channel blockers rather than beta-blockers.
Long-Term Outlook
One of the most persistent myths about a clean catheterization is that it means your heart is in the clear long term. The evidence says otherwise. Patients with INOCA carry an elevated risk of cardiovascular events compared to people without ischemia, including heart attacks, heart failure hospitalizations, strokes, and repeat cardiac procedures.24PubMed Central. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade There is also growing evidence that INOCA patients are at higher risk of developing heart failure with preserved ejection fraction, a type of heart failure where the heart muscle stiffens rather than weakens.
A recent systematic review and meta-analysis quantified these risks. The average rate of major adverse cardiovascular events in INOCA patients was about 1.9 per 100 patient-years. Breaking it down by subtype, patients with vasospastic angina had a combined rate of all-cause death and heart attack of roughly 0.7 per 100 patient-years, while those with microvascular angina had a slightly higher rate of about 1.0 per 100 patient-years.25PubMed Central. Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis These are not catastrophic numbers, but they are not zero either. For context, a healthy person of similar age without ischemia would have a lower baseline risk. The takeaway is that INOCA deserves ongoing monitoring and treatment, not just reassurance.
Why Women Are More Likely to Hear “No Blockage”
Women are disproportionately represented among INOCA patients. The estimated three to four million affected individuals in the U.S. skew female.1PubMed. Ischemia with No Obstructive Arteries (INOCA): A Review of the Prevalence, Diagnosis and Management This is not because women complain more or have lower pain thresholds. It reflects a genuine biological difference in how ischemic heart disease manifests across sexes. Women are more prone to microvascular dysfunction than to large-vessel plaque disease, meaning the standard diagnostic pathway, which is built around finding blockages in big arteries, is less likely to catch their particular form of heart disease.
This has real clinical consequences. Because women with cardiac ischemia more often present with open large arteries, they are more likely to be told nothing is wrong and sent home without further testing. Given the higher baseline probability of CMD in women, diagnostic approaches should account for that difference rather than stopping at a clean angiogram.26PubMed. Sex differences in diagnostic modalities of coronary artery disease: Evidence from coronary microcirculation If you are a woman who has been told your cath was normal but your symptoms persist, advocating for microvascular testing is not being difficult. It is pursuing the right diagnosis.
Exercise and Cardiac Rehabilitation
If you have been diagnosed with microvascular angina, exercise might sound counterintuitive. After all, physical exertion often triggers symptoms. But structured exercise programs appear to help rather than hurt. A meta-analysis of exercise-based cardiac rehabilitation for microvascular angina patients estimated a meaningful improvement in exercise capacity compared to controls, equivalent to a gain of roughly 4.4 ml/kg/min in peak oxygen consumption.27European Journal of Cardiovascular Nursing. Exercise-based cardiac rehabilitation effects on severity of angina, HRQoL and exercise capacity in patients with microvascular angina: systematic review and meta-analysis The evidence for effects on angina frequency and quality of life was less certain, but the exercise capacity findings were encouraging.
Beyond fitness numbers, there is a psychological dimension that matters. Many INOCA patients develop a fear of exertion, understandably so when exercise has previously brought on chest pain. A qualitative study following patients one year after completing a high-intensity exercise training program found that participants felt reassured they could be physically active safely, including at high intensity. For some, that meant incorporating exercise into daily life for the first time in years.28PubMed Central. Reassured on a background of vulnerability – people with microvascular angina 12 months after high-intensity physical exercise program Breaking the cycle of fear, avoidance, deconditioning, and worsening symptoms can be as valuable as any medication.
Experimental Therapies on the Horizon
The treatment landscape for CMD and INOCA is evolving quickly. Several classes of drugs are being investigated in clinical trials, reflecting the growing recognition that current options do not work well enough for many patients. Among the agents under study are colchicine (an old anti-inflammatory drug being repurposed), ivabradine (which slows heart rate through a different pathway than beta-blockers), SGLT2 inhibitors (originally developed for diabetes but showing cardiovascular benefits across a range of conditions), and soluble guanylate cyclase stimulators, which promote blood vessel relaxation. Researchers are even testing monoclonal antibodies that target inflammatory signaling molecules, based on the theory that chronic low-grade inflammation drives microvascular damage in some patients.29PubMed Central. Coronary microvascular dysfunction: a narrative review None of these are ready for routine use yet, but the breadth of the research pipeline is a sign that the field is taking INOCA seriously in a way it did not a decade ago. If current medications are not controlling your symptoms, asking your cardiologist about clinical trials may be worth the conversation.